



Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045

February 18, 2021

Dear Valued Customer:

Pfizer Hospital Business Unit (HBU) is discontinuing both its 4 mg/100 mL and 5 mg/100 mL premix presentations of Zoledronic Acid Injection. Unanticipated changes to the manufacturing process at our third-party supplier have necessitated an accelerated market exit and do not allow us to continue manufacturing at this time.

Pfizer does not expect significant impact for existing customers. Our standard vial presentation of Zoledronic Acid Injection 4 mg/5 mL (**NDC 00409-4215-01**) will continue to be manufactured. There are also premix alternatives from other manufacturers in the marketplace.

This premix discontinuation is effective immediately. The 4 mg/100 mL presentation is out of stock in the distribution centers, though there may be supply available through the wholesaler. The final release of the 5 mg/100 mL presentation is projected for February, but is limited and will primarily be used to fulfill backorders already in queue.

The below table includes details about last lots shipped and expiration date for the 4 mg/100 mL presentation to help you gauge expected shelf life. If you have other lots in your inventory, expiration dating should govern your actions.

NDC Number	Product Description	Package Size	Last Lots Shipped	Last Lots Exp Date	Last Date Shipped
00409-4229-01	Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) Flexible Container	20 x 1	BL57AD	07/30/2021	11/09/2020

Please reach out to your Pfizer Hospital sales representative or sales executive if you have any questions.

Thank you,

Melissa Kean Smetana
Senior Manager, Portfolio Premix, Specialty Solutions, and Micronutrients
Pfizer Hospital Business Unit.